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Development of a human 
primary gut‑on‑a‑chip to model 
inflammatory processes
Claudia Beaurivage1,2, Auste Kanapeckaite1, Cindy Loomans1, Kai S. Erdmann2, 
Jan Stallen1 & Richard A. J. Janssen1*
Inflammatory bowel disease (IBD) is a complex multi‑factorial disease for which physiologically 
relevant in vitro models are lacking. Existing models are often a compromise between biological 
relevance and scalability. Here, we integrated intestinal epithelial cells (IEC) derived from human 
intestinal organoids with monocyte‑derived macrophages, in a gut‑on‑a‑chip platform to model 
the human intestine and key aspects of IBD. The microfluidic culture of IEC lead to an increased 
polarization and differentiation state that closely resembled the expression profile of human colon 
in vivo. Activation of the model resulted in the polarized secretion of CXCL10, IL‑8 and CCL‑20 by IEC 
and could efficiently be prevented by TPCA‑1 exposure. Importantly, upregulated gene expression by 
the inflammatory trigger correlated with dysregulated pathways in IBD patients. Finally, integration 
of activated macrophages offers a first‑step towards a multi‑factorial amenable IBD platform that 
could be scaled up to assess compound efficacy at early stages of drug development or in personalized 
medicine.
Abbreviations
CCL-20  C–C Motif Chemokine Ligand 20
CD  Crohn’s disease
CML  Chronic myeloid leukemia
CXCL10  C-X-C motif chemokine 10
ECM  Extracellular matrix
EMT  Epithelial-mesenchyme transition
FDR  False discovery rate
HIO  Human intestinal organoids
HISC  Human intestinal stem cell
IBD  Inflammatory bowel disease
IEC  Intestinal epithelial cells
IFN-γ  Interferon gamma
IL-8  Interleukin-8
iPSC  Induced pluripotent stem cells
LPS  Lipopolysaccharide
M-CSF  Macrophage stimulating factor
PDMS  Polydimethylsiloxane
PIN  Percentage of inhibition
rh  Recombinant human
SLC  Solute carrier
UC  Ulcerative colitis
Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is a group of chronic relapsing 
inflammatory conditions of the gastrointestinal tract. Their pathogenesis is not fully understood yet. Neverthe-
less, they are thought to arise in genetically susceptible individuals in response to several factors such as diet, 
microbiota, smoking or environmental  factors1,2. Mechanistically, IBD patients may harbour genetic mutations 
in genes involved in the integrity of the intestinal epithelium, which allows microbiota to translocate in the 
intestinal tissue and initiate an inflammatory reaction leading to intestinal lesions showing excessive immune 
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cell  infiltration3. Immune cells recruited to the intestinal mucosa are generally sufficient to dial down inflamma-
tion and return the microenvironment to a normal status. However, IBD patients lack the required regulatory 
mechanisms or have aberrant activation of these immune cells, leading to a sustained inflammatory  state1,3. 
Notably, the intestinal tissue of actively inflamed IBD patients show a drastic increase of activated macrophages; 
the number of pro-inflammatory M1 macrophages will increase as the number of anti-inflammatory M2 mac-
rophages will  decrease4–6. Obviously, macrophages are not the only cell type playing a role in the pathogenesis 
of IBD; dendritic  cells7, innate lymphoid  cells8 as well as T helper  cells6 have also been shown to be involved or 
disbalanced through the disease progression.
Trying to understand the mechanisms behind the establishment of these diseases is particularly challenging, 
as modeling multi-factorial diseases in an in vitro environment is difficult. Current in vitro IBD models mostly 
rely on adenocarcinoma-derived Caco-2  cells9,10. Caco-2 cells have provided great insight in the importance of 
the epithelial barrier function in intestinal  inflammation11,12, however they do not represent the cellular diversity 
of the intestinal epithelium and therefore poorly reflect in vivo physiology. Furthermore, they fail to express 
some of the major inflammatory cytokines involved in IBD upon  stimulation13,14. On the other hand, human 
primary intestinal epithelial cells (IEC) are a physiologically relevant option that can easily be cultured as human 
intestinal organoids (HIO). HIO contain multiple epithelial cell types derived from the intestinal stem cells and 
therefore faithfully recapitulate the cellular diversity of the intestinal epithelium in vivo15,16. However, one major 
drawback of HIO is their enclosed lumen because of the spherical nature of organoids, making luminal drug 
exposure difficult. Additionally, HIO cultures lack tissue-tissue interactions, mechanical tension, as well as the 
integration of other cell types important to intestinal physiology such as immune and vascular cells. Thus, there 
is a major need for more complex and physiologically relevant intestinal organ culture systems.
Recently, the organ-on-a-chip technology has emerged as an alternative approach that offers different perfus-
able microchannels in which cell types of interest can be cultured together in an organ-like orientation using the 
support of an extracellular matrix (ECM)  gel17,18. A few gut-on-a-chip models have already been developed with 
adenocarcinoma-derived cell lines such as Caco-2 cells and HT-2912,19–22. Because of the limited physiological 
relevance of these intestinal cell lines, a few studies have created gut-on-a-chip models using HIO or iPSC-derived 
 organoids18,23–25. These studies clearly showed the augmented relevance of human primary models over Caco-2 
cells and even established co-cultures with microvascular endothelial cells and intestinal  myofibroblasts23,24. 
Importantly, the use of organ-on-a-chip technology transcends the limitation of ‘inside-out’ HIO as it allows 
the cells to grow in a monolayer that will cover all the surfaces of the microfluidic channel thus creating a 
tubular structure with an open lumen, allowing exposure to factors such as bacteria, cytokines or drugs in a 
localized manner. Despite the remarkable advance that these results represent, no study has yet applied their 
human primary gut-on-a-chip device for the recapitulation and investigation of disease-specific phenotypic 
characteristics of IBD. Furthermore, the lack of efficient treatment for IBD patients urges scientists to develop 
devices and models that allow screening of compounds in a relatively high-throughput manner. The commonly 
used PDMS-based chips lack the necessary scalability to perform such high throughput experiments and lead 
to absorption of small molecule  drugs26,27, making these inadequate for drug screening.
Herein, we report the establishment of a gut-on-a-chip model composed exclusively of patient-derived human 
primary material. Monocyte-derived macrophages and HIO from different donors were integrated in the mem-
brane-free 3-lane OrganoPlate platform, a higher throughput alternative to PDMS-based chips that would allow 
compound screening due to its glass composition. We show that the microfluidic culture of HIO leads to an 
increased polarization and differentiation profile of the cells over standard organoids culture. Importantly, the 
transcriptome of the microfluidic gut-on-chip resembles that of adult human normal colon in vivo. We induced 
IBD hallmarks by triggering the gut-on-a-chip with lipopolysaccharide (LPS) and interferon-gamma (IFN-γ), 
leading to the activation and increase cytokine production of both HIO and macrophages. Our model could 
individually pinpoint cell type-specific cytokine production, in both apical and basal channels simultaneously, 
allowing us to fully characterize the induction of the inflammatory phenotype. Induction of inflammation in 
HIO was also confirmed by transcriptomics of the microfluidic gut-on-a-chip. Finally, the suitability of the 
model to perform compound exposure experiments was confirmed. Our proof-of-concept experiments show 
that known anti-inflammatory compound TPCA-1 prevents the establishment of the inflammatory phenotype 
in a dose-dependent manner. In summary, our results highlight the suitability of our in vitro microfluidic gut-
on-a-chip model to mimic key physiological aspects of the intestine and further apply them to IBD modelling 
and potentially large-scale screening in the search for novel IBD treatments.
Results
Primary human gut‑on‑a‑chip developed using biopsy‑derived organoids. Presently, the unique 
source for primary intestinal cells are organoid cultures derived from patients’ biopsies. We set out to develop 
a gut-on-a-chip model integrating human biopsy-derived epithelium under fluid flow to determine if such a 
model would better reflect the in vivo situation. HIO cultures were established using intestinal crypts derived 
from macroscopically normal regions of intestinal endoscopic biopsies (Table 1). After stabilization and expan-
sion of the cultures, HIO were dissociated and seeded in the upper channel of the 3-lane OrganoPlate, on top of 
an ECM gel contained in the middle channel (Fig. 1A).
The composition of the human intestinal stem cell (HISC) medium previously published by Hans Clevers’ 
 group28 (Table 2) was optimized to favour IEC attachment in the OrganoPlate and ALK5 inhibitor A83-01 was 
withdrawn from the formulation (attachment medium). IEC kept in attachment medium for the full duration of 
the experiment started to become mesenchymal as indicated by the upregulation of SM22 expression (Fig. S1). 
By switching back to HISC medium two days after seeding, IEC did not gain mesenchymal markers expression 
but did form confluent epithelial monolayers in a more robust and reproducible way (Fig. S1).The IEC first 
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adhered to the ECM gel before they could cover all the walls of the upper microfluidic channel, therefore forming 
a polarized epithelial tubule, as previously reported in similar gut-on-a-chip  models19,29.
After 10 days of microfluidic culture, the polarization status of the IEC was assessed (Fig. 1B). The localiza-
tion of E-CADHERIN at cell–cell junctions indicated the formation of zonula adherens junctions. Similarly, 
EZRIN expression was present and its localization was restricted to the apical surface of IEC, confirming proper 
polarization of the cells. IEC showed unified organization of ACTIN filaments further supporting the conserved 
apical-basal polarity of the IEC. The expression level of polarization markers was also confirmed at the mRNA 
level by qPCR by comparing HIO grown in standard Matrigel droplets (static) and IEC grown in an Organoplate 
subjected to fluid flow (microfluidic). The microfluidic culture of HIO increased the expression of polarization 
markers CDH1, TJP1, OCLN, EZR and VIL1 when compared to static HIO culture (Fig. 1C). These results were 
confirmed in additional HIO donor (Fig. S2A).
Table 1.  HIO donor information.
HIO donor Biopsy location Gender donor Age donor (years old) Supplier
1 Rectum Female 9 Hubrecht Institute
2 Colon Male 72 Tissue Solutions














































































Figure 1.  IEC cultured under microfluidic conditions show higher expression of polarization and 
differentiation markers. (A) Schematic representation of the model. One microfluidic chip is composed of 
three channels: the upper channel (A), middle channel (B) and lower channel (C). Each channel has dedicated 
inlets (A1, B1, C1) and outlets (A3, B3, C3). Imaging is possible through the observation window (B2). The 
top view shows the two perfusion channels flanking the middle channel where an extracellular matrix (ECM) 
gel is seeded. The PhaseGuides allow the ECM gel to form a meniscus, allowing barrier-free culture. The 
transversal view shows the IEC forming an epithelial tubule in the upper channel against the ECM gel. Medium 
perfusion is started by placing the OrganoPlate on an interval rocker. Illustration created with Adobe Illustrator 
software (version22.1, https ://adobe .com/produ cts/illus trato r). (B) Representative 20X stitched photographs of 
zonula adherens marker E-CADHERIN, apical polarization marker EZRIN, polarization marker ACTIN and 
goblet cell marker MUC2 in HIO grown in microfluidic conditions for 10 days. Blue depicts nuclei by DAPI 
staining. Images were created with the Image J software (version 1.47v, https ://image j.nih.gov/ij/). (C,D) mRNA 
expression level of polarization markers (C) CDH1, TJP1, OCLN, EZR and VIL1 and differentiation markers 
(D) ALPI, SI, MUC2, MUC5AC, LYZ and CHGA in HIO donor 2. HIO were grown in standard static culture or 
in monolayers subjected to fluid flow (microfluidic) for 8 days. Graph shows average relative expression values 
normalized to RPS18, HPRT1, GUSB and YWHAZ ± SEM with unpaired t-test compared to standard HIO 
culture (n = 3).
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We further assessed the differentiation state of the IEC in the microfluidic chip. The presence of enterocytes, 
the predominant cell type of the intestinal epithelium, was confirmed by the successful mRNA detection of the 
brush border enzymes ALPI and SI (Fig. 1D). The presence of goblet cells, was highlighted by a MUC2 staining 
of IEC grown under fluid flow for 10 days (Fig. 1B) and the mRNA levels of MUC2 and MUC5AC expression 
(Fig. 1D). The microfluidic culture of IEC led to an increase of the expression of these markers at the mRNA 
level compared to the static HIO culture. As the cells used in this study are derived from distal colonic and rectal 
portions of the gastrointestinal tract (Table 1), limited expression of Paneth cell marker LYZ and enteroendocrine 
cell marker CHGA could be detected and was not significantly upregulated upon microfluidic culture of the 
cells (Fig. 1D). These results were confirmed in additional HIO donor (Fig. S2B). Furthermore, the microfluidic 
culture seemed to increase the general differentiation state of IEC at the expense of proliferation as noted by the 
upregulation of expression of transcription factors involved in differentiation programs HES1, CDX2 and KLF4 
and a decrease of expression of stem cell marker LGR5 (Fig. S3A,B). Interestingly, we found stem cell marker 
OLFM4 expression to be upregulated in microfluidic-grown IEC (Fig. S3C). Overall, these results indicate that 
IEC can be grown under microfluidic conditions and that fluid flow increases the expression of polarization and 
differentiation markers.
Transcriptomic comparison of the microfluidic gut‑on‑a‑chip versus standard HIO culture. To 
further determine whether the microfluidic culture of IEC affects the expression of physiologically relevant 
genes, we carried out transcriptome-wide analysis of IEC from three different donors. We performed a head-to-
head transcriptomic comparison of the established gut-on-chip cultures with the original HIO cultures used for 
chip seeding. A non-biased analysis of all 4,921 significantly up- and down-regulated genes was performed and 
the top 30 differentially expressed genes in microfluidic vs standard HIO culture conditions is shown at Fig. 2A 
(PCA graph can be found at Fig. S4A). In order to uncover the presence of physiologically relevant pathways, 
Gene Ontology (GO) enrichment analysis for all differentially expressed genes was executed. Interestingly, the 
analysis uncovered that gene sets involved in digestion, intestinal transport and hormone metabolic process were 
differentially expressed between microfluidic culture and static cultures (Fig. 2B). These results were confirmed 
by qPCR, where the microfluidic culture increased the expression of intestinal enzymes SI and ALPI (Fig. 1D).
Additionally, we compared the samples’ transcriptomic results with gene profiles of distinct regions of the 
human gastrointestinal tract (ileum, jejunum, duodenum and colon)30,31. As the organoids cultures were derived 
from distal colon biopsies (Table 1), a panel of genes defining colonic tissue was selected for this purpose. Within 
this panel of genes, only subtle variations between static and microfluidic samples could be observed. Overall, 
the profiles resembled those of fresh human normal colon and the microfluidic culture did not alter tissue 
phenotype (Fig. 3). We also compared our datasets to a Caco-2 gut-on-a-chip and Transwell models published 
 previously24 and the differences were drastic; Caco-2 cells had lower expression for all tested genes and were more 
similar to small intestine tissue sections (Fig. S5). Once again, the microfluidic culture of Caco-2 cells did not 
have a striking effect on the expression of this specific set of genes over Transwell static culture. In conclusion, 
it appears that HIO have a higher expression of genes involved in intestinal transport and digestion pathways 
when they are cultured under microfluidic conditions, while their overall colonic tissue phenotype is preserved.
Activation of the gut‑on‑a‑chip towards an inflammatory state. Following the establishment of 
a physiologically relevant gut-on-a-chip, we wanted to determine whether our model could recapitulate main 
characteristics of intestinal inflammation. To do so, the microfluidic gut-on-a-chip was exposed to LPS and IFN-
γ. IFN-γ is one of the most highly upregulated cytokines after microbial invasion and in chronic inflammatory 
diseases including  IBD1,32. It is produced by innate lymphoid cells and has been shown to selectively alter the 
permeability of the intestinal epithelium, allowing the translocation of bacterial components to the intestinal 
 tissue33–35. We applied the inflammatory trigger on both the apical and basolateral side in order to promote the 
complete activation and differentiation of macrophages into M1 macrophages, work that will be presented in 
the last section of this report. However, we did control asymmetric responses to the inflammatory stimuli in 
Table 2.  Composition of the HISC medium.
Constituent Supplier (Catalog number) Final concentration
rh R-spondin 3 R&D systems (3500-RS/CF) 0.5 µg/mL
rh Noggin PeproTech (120-10C) 0.1 µg/mL
B27 supplement Gibco (17504) 1X
N-Acetyl-L-cysteine Sigma Aldrich (A9165) 1.25 mM
Nicotinamide Sigma Aldrich (N0636) 0.01 M
rh EGF PeproTech (AF-100-15) 0.05 µg/mL
rh Gastrin 1 Tocris (3006) 0.005 µM
Primocin InvivoGen (ant-pm) 0.1 mg/mL
A83-01 Tocris (2939) 0.5 µM
SB202190 Sigma Aldrich (S7067) 0.01 mM
Y-27632 Abmole (M1817) 0.01 mM
Wnt3a conditioned medium - 50%
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Figure 2.  IEC cultured under microfluidic conditions show higher expression of genes involved in digestion, 
intestinal transport and hormone metabolic process. (A) Heatmap representation of the top 30 differentially 
expressed genes between standard and microfluidic HIO culture in three HIO donors. Higher levels of 
expression are represented in red and lower levels in blue. (B) Differentially-expressed genes between standard 
and microfluidic HIO culture were grouped under Gene ontology (GO) functional pathways. Circle size 
represents the number of genes differentially expressed in each GO pathway and lines link individual genes to 
their related GO pathways.
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HIO (Fig. S6). Overall, there were no differences on cytokine production whether the LPS was applied apically 
or basally with IFN-γ kept on the basal side only. However, when LPS and IFN-γ were simultaneously applied 
on both apical and basal sides, the apical release of cytokines IL-6 and GM-CSF were increased, while IL12-p70 
remained constant and cytokines IL-1β and CXCL10 were decreased (Fig. S6).
The induction of inflammatory conditions in the gut-on-a-chip was first confirmed by RNA-sequencing of 
non-triggered and triggered samples from three HIO donors cultured in microfluidic conditions. A non-biased 
analysis of all 1,807 significantly up- and down-regulated genes was performed and the top 30 differentially 
expressed genes in triggered vs untriggered HIO grown in microfluidic conditions is shown at Fig. 4A (PCA 
graph can be found at Fig. S4B). All genes differentially expressed between the two experimental groups were 
assembled into functional GO pathways. When the gut-on-chip model was triggered with of LPS and IFN-γ, 
pathways involved in the regulation of IFN-γ/TNF-α/IL-1 responses, in the activation of the innate immune 
response and in the response to bacterial factors were over represented compared to the non-triggered condition 
(Fig. 4B). We used Metacore to map the top 30 differentially expressed genes against available disease maps and 
observed that they correlated strongly with IBD (p-value 7.402E-6, FDR 5.796E-5) and, to a lesser extent, with 
gastrointestinal diseases in general (p-value 1.002E-2, FDR 1.917E-2). All top scoring pathologies did relate to 
the gastrointestinal tract or inflammation (Fig. 4C) and more detailed analysis of the perturbed pathways further 
confirmed that the gene set identified in the triggered cultures is involved in immune regulation at many differ-
ent levels (Fig. 4D). These results confirmed that the trigger, composed of LPS and IFN-γ, successfully induced 
a pro-inflammatory state in the IEC and support the relevance of the model.
Anti‑inflammatory compound exposure. In an attempt to tone down the inflammation and assess the 
potential of the gut-on-a-chip model for drug discovery, we used TPCA-1, a known anti-inflammatory com-
pound (Table 3). TPCA-1 is a selective inhibitor of human IκB kinase-2 (IKK-2) that inhibits production of pro-
inflammatory cytokines in vitro and in vivo and inhibits NF-κB nuclear  localization19,36,37. Apical and basal pro-
duction of CXCL10, IL-8 and CCL-20 were efficiently inhibited in a dose-dependent manner in IEC (Fig. 5A–C). 
At IC50 concentrations (Fig. 5E), viability was not significantly altered and only the highest concentration of 
20 µM significantly decreased viability (Fig. 5D). Interestingly, TPCA-1 always decreased basal production of 
cytokines more efficiently than their apical production (Fig. 5E). These results demonstrate that the gut-on-a-
chip model could be a suitable alternative to standard organoid technology, which is of limited use in compound 
evaluation due to its inside-out configuration. 
Matrigel Microfluidic

















































































Figure 3.  RNA expression profiles of HIO donors resemble human colonic mucosa. Heatmap representation 
of the RNA expression profile of 72 genes defining colonic identity in 3 HIO donors grown in microfluidic or 
standard HIO culture conditions for 8 days, compared with human normal colon from study  GSE925431 and 
human normal small intestine sections (duodenum, jejunum, ileum) from study  GSE1493830. Genes with higher 
levels of expression are represented in red and genes with lower levels of expression in blue.
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Addition of a cellular immunological component. As previously reported, M1 macrophages are over-
represented and activated in the lamina propria of IBD patients and have been shown to contribute to IBD 
 physiopathology4,5. To mimic this key feature of IBD, monocyte-derived macrophages were embedded in the 
ECM gel of our gut-on-a-chip and were allowed to directly interact with the intestinal epithelium due to the 
absence of physical barrier between the microfluidics channels (Fig. 6A). Once the IEC formed complete epi-
thelial tubules, the co-culture was triggered with LPS and IFN-γ in both apical and basal channels, allowing the 
macrophages to polarize into M1 inflammatory macrophages, as demonstrated by an increase in TNF-α and 
IL-6 secretion (Fig. 6).
In order to characterize the inflammatory state of our model in more detail, we assessed the effect of the 
trigger on cytokine production by the epithelium and macrophages individually, as well as on both cell types. 
The apical and basal production of TNF-α, CXCL10, IL-6, IL-12p70, GM-CSF and IFN-γ were assessed for each 
mono-culture and the co-culture (Fig. 6B–F). From the cytokines analysed, only CXCL10 production was not 
upregulated by macrophages after trigger (Fig. 6C). In IEC, production of TNF-α, IL-6, IL-12p70 and GM-CSF 
were upregulated only on the basolateral side upon trigger (Fig. 6B,D-F), while CXCL10 production was upregu-
lated in both the apical and basolateral compartments (Fig. 6C). After triggering the co-culture, production of 
TNF-α and GM-CSF were increased only at the basolateral side (Fig. 6B,F), whereas both the apical and basolat-
eral production of CXCL10, IL-6 and IL-12p70 were increased (Fig. 6C-E). Interestingly, production of IL-12p70 
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Figure 4.  Induction of inflammatory conditions upregulates pathways involved in cytokine and immune 
signaling in IEC. (A) Heatmap representation of the top 30 differentially expressed genes between normal 
(untriggered) and inflammatory conditions (LPS 100 ng/mL, IFN-γ 20 ng/mL) in 3 different HIO donors. IEC 
were grown under microfluidic conditions for 8 days and triggered for 24 h. Heatmap shows gene expression 
levels (adjusted p value). Genes with higher expression values are shown in red and genes with lower expressions 
values in blue. (B) Based on significantly changed gene sets between normal and inflammatory conditions, 
functional Gene ontology (GO) pathways were isolated. Circle size represents gene counts and color gradation 
represents adjusted p values. (C,D) The top 30 differentially expressed genes were queried against toxic 
pathologies (C) and pathways (D) in Metacore. Graphs show false discovery rate (FDR) values.
Table 3.  Compound used in the study.
Generic name CAS Concentration Diluent Supplier
TPCA-1 507475-17-4 10 mM DMSO Sigma Aldrich (Saint Louis, MO, USA)
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and IL-6 were synergized in the co-culture (Fig. 6D,E). On the contrary, IEC showed an immunoregulatory 
effect on the apical production of TNF-α and GM-CSF production by macrophages in the co-culture (Fig. 6B,F).
To support the relevance of these findings, we investigated the mRNA expression of all analytes in colonic 
mucosal biopsy samples of control and IBD patients from previously published  datasets38. The expression of all 
analytes, except IL12A, IL12B and CSF2, were found to be upregulated in the mucosa of patients with active UC 
or CD (Fig. S7). Overall, our results show that this trigger mixture could successfully induce an inflammatory 
state in the co-culture of HIO and macrophages, resulting in the upregulation of relevant epithelial and immune 
cytokines.








































































































IC50 (µM) CXCL10 IL-8 CCL-20
Apical 2.11 2.31 4.11
Basal 1.26 2.15 2.29
Figure 5.  Exposure to TPCA-1 decreases inflammatory cytokine production by IEC. (A–C) Apical and basal 
percentage of inhibition (PIN) of CXCL10 (A) IL-8 (B) and CCL-20 (C) after TPCA-1 treatment. IEC from 
HIO donor 1 were grown under microfluidic conditions for 6 days before being exposed to TPCA-1 at the 
indicated concentrations. After 2 h of TPCA-1 exposure, cells were triggered for 24 h (LPS 100 ng/mL, IFN-γ 
20 ng/mL) in the continuous presence of TPCA-1. Dots represent the PIN mean normalized to triggered but 
TPCA-1 untreated IEC (T +). The line depicts a non-linear regression between [TPCA-1] and cytokine secretion 
(n = 4–5). (D) Viability of IEC after 72 h of TPCA-1 exposure. Bars represent the percentage of viable cells 
average ± SEM with one-way ANOVA with Dunnett’s post-hoc test compared to triggered but TPCA-1 untreated 
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Discussion
We report here the development of an in vitro model of the human intestine by integrating the organ-on-a-chip 
technology with organoid-based methods for culture of primary IEC from colorectal biopsies. A few gut-on-
a-chip models integrating biopsy-derived or iPSC-derived IEC have been published  recently24,25,39,40. However, 
none of them has addressed the importance of the immune component nor its implication to the study of IBD. 
Our gut-on-a-chip model differs from previous models by not only integrating primary human macrophages 
together with IEC, but also by inducing an inflammatory state of the epithelium similar to the one observed in 
IBD patients.
Firstly, we confirmed that all differentiated cell types present in the HIO were also represented in the gut-on-a-
chip model. Upon microfluidic culture, the mRNA expression of markers associated with enterocytes and goblet 
cell differentiated cell types of the intestinal epithelium, as well as transcription factors favouring differentiation 
were increased, while markers for proliferation were decreased. Interestingly, stem cell marker LGR5 expression 
was decreased by fluid flow as observed by previous  studies24, while OLFM4 expression was increased. Recent 
studies have demonstrated that OLFM4 was expressed at very low levels in the foetal intestine and in HIO cul-









































































































Figure 6.  Induction of inflammatory conditions increases cytokine secretion of macrophages and IEC. (A) 
Schematic representation of the microfluidic co-culture modified from Fig. 1A. Macrophages are directly 
embedded in the ECM gel on which the epithelial tubule lay against. PhaseGuides allow a barrier-free culture. 
Illustration created with Adobe Illustrator software (version22.1, https ://adobe .com/produ cts/illus trato r). 
(B–F) Apical and basolateral secretion of TNF-α (B), CXCL10 (C), IL-6 (D), IL-12p70 (E) and GM-CSF (F) in 
macrophages (MF), IEC from HIO donor 1 and the co-culture of both at Day 8 after a 24 h trigger (LPS 100 ng/
mL, IFN-γ 20 ng/mL). Bars represent average cytokine production [pg/mL] ± SEM (n = 3–5).
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positive cells might be linked to this observation and more investigation is necessary, it could however suggest 
that our gut-on-a-chip model has reached a higher level of maturity over static HIO culture.
Furthermore, IEC grown as a monolayer on an ECM gel under flow have higher expression of genes with a 
role in important intestinal functions such as digestion, intestinal transport and hormonal regulation over static 
HIO spheroids. This suggests that microfluidic gut-on-a-chip models might more adequately reflect organ-level 
functions over conventional organoids. Comparison of the expression level of a set of genes involved in colonic 
identity between microfluidic samples and in vivo intestinal segments revealed that there is no significant impact 
of microfluidic culture on intestinal phenotype. HIO donors, whether cultured in static or microfluidic condi-
tions, highly resembled the human colonic mucosa. The differences between the general intensities of the signals 
could be explained by the different technologies used. Despite this difference in signal intensity, the relative gene 
expression profile was decidedly similar to that of genes in the human colon, making our model particularly 
appropriate for UC modelling, which mainly affects that area of the gastrointestinal tract. Previously published 
Transwell and gut-on-a-chip Caco-2 models, on the other hand, more closely resembled the human small intes-
tine. One should therefore be careful using Caco-2 cells to study colon-specific mechanisms and pathologies 
such as UC, as our results suggest that they strictly represent cells from the small intestine, despite the fact that 
they have been described to express both enterocytes and colonocytes  markers10. Furthermore, in both the HIO 
and Caco-2 case, the microfluidic culture did not significantly alter the expression of genes involved in intestinal 
phenotype. Despite the lack of regulation of RNA expression profiles of this specific set of genes, other genes 
involved in intestinal transport and metabolism were highly represented by microfluidic culture. Furthermore, 
other studies have also shown that HIO gut-on-a-chip models led to increased intestinal functions compared to 
organoids or Caco-2 gut-on-a-chip  models24,39. Thus, for assessments such as drug metabolism and response to 
nutrients, microfluidic models might be more informative of the in vivo situation.
In this study, we have used the original HISC medium recipe as originally published by Hans Clevers group 
presented at Table 228. To optimize IEC attachment in the microfluidic plate, ALK5 inhibitor A83-01 was with-
drawn for the first 48 h, as previous studies have also  done43. When withdrawn for 48 h, we did not obverse any 
upregulation of EMT markers. However, it cannot be excluded that the removal of A83-01 could be responsible 
for some molecular changes observed in our RNA-sequencing analyses. However, we did not observe an upregu-
lation of pathways regulated by TGF-β such as EMT, proliferation or apoptosis. We have, in fact, observed a clear 
reduction in proliferation markers expression.
We next inquired whether the gut-on-a-chip could be applied to model inflammatory responses. To do so, 
we applied a mixed trigger composed of bacterial LPS and cytokine IFN-γ to the microfluidic model. We first 
confirmed the induction of an inflammatory state by RNA-sequencing of HIO. Pathways involved in cytokine 
regulation and bacterial response that are dysregulated in IBD patients were found to be overrepresented in trig-
gered IEC, confirming the general inflammatory state of the model and supporting its physiological relevance.
Naturally, IBD is a multi-factorial disease that cannot be solely recapitulated by one cell type. Macrophages, 
which were shown to be overrepresented and activated in  IBD4,5, were therefore included into our model to 
increase its complexity. Upon trigger, macrophages were activated into pro-inflammatory M1 macrophages 
and secreted immune-relevant cytokines TNF-α and IL-6. The inflammatory trigger also activated IEC, which 
in turn, secreted epithelial cytokines. This was particularly the case for IL-12p70 and IL-6 whose secretion was 
synergized in the co-culture. Contrarily, IEC showed an immunoregulatory effect on the apical production of 
TNF-α and GM-CSF production by macrophages in the co-culture. IEC are capable of secreting modulators 
that can modulate the cytokine secretion of macrophages, such as cholecystokinin and glucagon-like peptide 
(GLP) 1 and  244,45. Particularly, IEC have been reported to induce differentiation of normal macrophage into a 
tolerogenic phenotype resembling intestinal  macrophages46. In all cases, the basolateral production of inflam-
matory cytokines upon trigger was always greater than the apical production, suggesting that IEC respond to an 
inflammatory state by secreting analytes at the basolateral side. The reason for this could be that IEC are involved 
in recruitment of immune effectors residing in the underlying lamina propria or circulating in the blood through 
the secretion of chemokines and cytokines at the basolateral  site47.
Our study did not assess whether other changes in the medium composition would further affect IEC dif-
ferentiation and the cellular responses engaged. Research groups have now shown that innate immune responses 
of IEC are modulated by the removal of Wnt3a conditioned medium, which alters the state of differentiation 
of IEC. For instance, removal of Wnt3a was shown to induce MHC II expression which can in turn promote 
TLR-triggered innate immune  responses48. Similarly, the presence of anti-oxidants in the HISC medium have 
also been shown to influence innate immune responses of  IEC49. Notably, jejunal organoids cultured in medium 
devoid of antioxidants were more responsive to host and microbial inflammatory signals. While we demonstrate 
that innate immune responses were successfully induced in our model, it would become important in the future 
to assess whether the modification of the HISC medium composition alters those responses in IEC and whether 
the IEC-immune cell relationship is consequently affected. Furthermore, our study focused on the effect of 
microfluidic culture and pro-inflammatory stimulation on the intestinal epithelium, but we did not assess the 
contribution of individual cell types to the phenotype. It would be of particular interest to investigate cellular 
changes occurring in goblet and Paneth cells during co-culture with macrophages, as abnormal cell function 
has been described in IBD  patients50,51.
One of the drawbacks of the organoid methodology is their enclosed lumen, making drug exposure studies 
difficult. In addition, it does not allow to simultaneously measure the secretion of analytes at both the apical and 
basolateral site. The novel gut-on-a-chip model presented in this study transcends these limitations and allowed 
IEC exposure to TPCA-1 compound in a polarized manner. TPCA-1, by selectively binding the ATP pocket of 
IKK-2, prevents the phosphorylation of inhibitor of NF-κB (IκB), preventing NF-κB nuclear translocation and 
the activation of genes involved in inflammation and other immune  responses36. TPCA-1 markedly reduced the 
epithelial production of CXCL10, IL-8 and CCL-20 by IEC. The compound has previously been shown to reduce 
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IL-8 by HT-29  cells52 as well as CXCL10, IL-8 and CCL-20 production by Caco-2  cells19. Furthermore, NF-κB has 
been shown to be activated in mucosal biopsies of patients with active IBD and the use of steroids, by decreasing 
NF-κB activity, have shown to reduce clinical symptoms of  patients53. Hence, our proof-of-concept experiment 
show preliminary evidence that our model could potentially be used to assess the efficacy of drug candidates 
on cytokine secretion in the intestine. Importantly, our model offers numerous advantages over Caco-2 models 
currently used in drug absorption  studies54,55. Indeed, although Caco-2 cells have been found to express a large 
number of enzymes and transporters present in the normal human intestinal epithelium, studies suggest that 
there are variations between gene expression profiles of transformed epithelial cell lines like Caco-2 and the 
normal human intestinal  epithelium56,57. This could, in turn affect the accuracy and relevance of results obtained 
in this system. Furthermore, while some studies show the limited presence of MUC2 expression in Caco-2 cells 
under specific  conditions21, they are overall considered enterocyte-like only and do not reflect the diversity of the 
intestinal epithelium. By using human primary IEC derived from biopsies, we addressed the limitations incurred 
by the use of Caco-2 cells. In addition, culturing the IEC in microfluidic conditions corrected the inside-out 
configuration of HIO and increased the expression of intestinal transporters such as SLC superfamily members 
that are known to be important for the transport of drugs through the  epithelium58.
Our novel primary human gut-on-a-chip model could therefore not only be used to study drug transport, 
absorption and toxicity but could also be potentially of use in studying intestinal development, tissue-tissue 
interactions, host–pathogen connections as well as regenerative medicine. In the future, the implementation of 
other cell components participating in IBD pathogenesis, such as supplementary immune cell types to reflect 
the heterogeneity of the mucosal immune system, would allow us to reflect in vivo physiology more closely. 
Similarly, access to IBD-patient material could allow us to investigate patient-specific disease mechanisms and 
therapy response, opening the doors to personalized medicine. The advent of the organ-on-a-chip technology 
allows us to separately control physical and mechanical factors (e.g., fluid flow) as well as cellular components 
to better understand and model intestinal homeostasis and diseases of the gastrointestinal tract such as IBD.
Methods
Ethics statement. The research described here has been performed according to applicable Dutch national 
ethics regulations and was conducted within Galapagos BV (Leiden, NL). The use of human cells and associated 
protocols were approved by the Galapagos biobanking committee. Scientists from Galapagos BV are qualified to 
perform research using human material and have appropriate facilities and equipment available to comply with 
applicable laws, regulations and internal rules related to handling and storage of the material. The human mate-
rial was obtained from Sanquin (Amsterdam, NL), Tissue Solutions (Glasgow, UK) or the Hubrecht Institute 
(Utrecht, NL). The suppliers have confirmed to Galapagos BV that informed consent from the donors to use the 
material for research purposes was received. The cells were solely used for target and drug discovery and were 
not used for human experimentation or therapy. All material is and will remain anonymized.
In vitro culture of human intestinal organoids. Intestinal crypts were isolated from intestinal biopsies 
as previously  described15,28, resuspended in Matrigel (Corning) and polymerized at 37  °C. Human intestinal 
organoids (HIO) were grown in Human intestinal stem cell (HISC)  medium15,28, passaged at a ratio of 1:10 to 
1:12 every 10–14 days and used between passages 4 and 15. The final composition of the HISC medium is shown 
at Table 2. HISC medium was produced in Advanced DMEM/F-12 (Gibco, #12634) supplemented with 1%v/v 
Glutamax (Gibco, #35050), 1%v/v HEPES (Gibco, #15630) and 1%v/v Pen/Strep (Gibco, #15140). 2X-concen-
trated HISC medium was diluted in a 1:1 ratio in Wnt3a conditioned medium. To produce Wnt3a conditioned 
medium, L Wnt3a cells (CRL-2647) were grown in Advanced DMEM/F-12 (Gibco, #12634) supplemented with 
10% FBS (Bovogen, #SFBS), 1%v/v Glutamax (Gibco, #35050), 1%v/v HEPES (Gibco, #15630) and 1%v/v Pen/
Strep (Gibco, #15140) in presence of 125 µg/mL Zeocin (Thermo Fisher, #R25001).
Isolation and in vitro culture of human macrophages. Human peripheral blood mononuclear cells 
(PBMCs) were isolated from buffy coats using density gradient centrifugation on Ficoll-Paque according to 
manufacturer protocol. Monocytes were positively isolated using magnetic CD14 microbeads (Miltenyi, #130-
050-201) and were cultured in a low-attachment flask for 5 days in RPMI (Gibco, #72400) supplemented with 
heat-inactivated FBS (Gibco, #F8067), Pen/Strep (Gibco, #15140) and [100 ng/mL] rh M-CSF (ImmunoTools, 
#11343115) to differentiate towards macrophages.
Gut‑on‑a‑chip coating, seeding and culture. Coating of gut‑on‑a‑chip without macrophages. An 
ECM gel was prepared by mixing 1 M HEPES (Gibco, #15630), 37 g/L  NaHCO3 pH9.5 (Sigma Aldrich, #S5761) 
and rat-tail Collagen I (Cultrex, #3447–020-01) at a 1:1:8 v/v/v ratio (HEPES/NaHCO3/Collagen I). A 1.6 µL 
volume was dispensed in the middle channel of a 3-lane 400 μm OrganoPlate (Mimetas, #4003-400-B) and let to 
polymerize for 15 min in a 37 °C environment in presence of 5%CO2.
Coating of gut‑on‑a‑chip with macrophages. Macrophages were harvested, pelleted and resuspended in the 
ECM gel at a concentration of 1.1 × 106 cells/mL. Embedded macrophages were seeded in the middle lane of a 
3-lane 400 μm OrganoPlate (Mimetas, #4003-400-B) in a 1.8 µL volume, thus making 20,000 macrophages/chip. 
Coated plates were placed in a 37 °C incubator supplemented with 5%  CO2 for 15 min until the ECM solidified.
Gut‑on‑a‑chip seeding. During ECM polymerization, HIO were retrieved from Matrigel droplets and made 
single cells using TryplExpress (Gibco, #12,605) and mechanical dissociation as previously  reported15,28. 100,000 
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HIO cells were seeded in a 2 µL volume in the upper channel of the OrganoPlate and left to adhere against the 
gel for 45 min. After incubation, 50 µL of HISC medium devoid of A83-01 (attachment medium) was added to 
the upper inlet and the plates were returned to the incubator at a 70° angle for 4–6 supplementary hours. After 
4–6 h, 50 µL of attachment medium was added to all remaining inlets and outlets and the plates were placed 
back in the incubator without medium perfusion for 24 h. On Day 1, plates were placed on an interval rocker 
(Perfusion Rocker Mini, Mimetas) switching between a + 7° and − 7° inclination every 8 min (37 °C, 5%  CO2) 
leading to a 121.2 µl/hr perfusion  rate59. Attachment medium was replaced with HISC medium two days after 
seeding, and HISC medium was refreshed every three days after that. During all experimentation, the lower 
channel medium was supplemented with [100 ng/mL] rh M-CSF (ImmunoTools, #11,343,115) to maintain the 
macrophages differentiated.
Gut‑on‑a‑chip activation. 6 days after seeding, the co-culture was activated using [100 ng/mL] LPS (Sigma, 
#L3024) and [20 ng/mL] rh IFN-γ (ImmunoTools, #11343534) in HISC medium in both upper and lower chan-
nels for 16–24 h. Effluents were collected from apical (upper channel) and basolateral (lower channel) compart-
ments at specified times and kept at − 20 °C until downstream analyses were performed.
Gut‑on‑a‑chip exposure to compound. 6 days after seeding, the co-culture was pre-exposed to compound con-
centrations ranging from 0.02 µM to 20 µM in 0.22% DMSO in upper and lower channels for 2 h. After 2 h, the 
trigger (100 ng/mL LPS, 20 ng/mL IFN-γ) in presence of 0.02–20 µM compound was applied in upper and lower 
channels. Effluents were collected from apical and basal channels 24 h and 72 h after compound exposure and 
viability was assessed 72 h after compound exposure.
Assessment of cytokine production. The concentration of Granulocyte–Macrophage Colony-Stimu-
lating Factor (GM-CSF), Interleukin-12 unit p70 (IL-12p70), Interleukin-6 (IL-6), Interleukin-8 (IL-8/CXCL8), 
IFN-Gamma-Inducible Protein-10 (IP-10/CXCL10), Macrophage Inflammatory Protein-3 (CCL-20/MIP3A) 
and Tumor Necrosis Factor-Alpha (TNF-α) in collected effluents was determined by a human multiplex assay 
(Thermo Fischer) on a Luminex FlexMap 3D (Merck Millipore) according to manufacturer protocol.
Assessment of viability. 72 h after compound treatment, WST-8 reagent (Sigma Aldrich) was mixed in 
HISC medium in a 1:10 ratio and 25µL was added to upper and lower inlets and outlets. Plates were incubated 
at 37 °C for 4 h and absorbance signals were measured (450 nm monochromator) with a multi‐well plate fluor-
imeter (Envision, Perkin Elmer).
Immunocytochemistry. Cells were fixed and prepared for immunohistochemistry as previously 
 described19,29. The primary antibodies used were anti-E-CADHERIN (Abcam #AB1416, 1:100), anti-EZRIN 
(Invitrogen #MA5-13,862, 1:50), anti-MUC2 (Invitrogen #MA5-12,345, 1:50). Secondary antibody used was 
donkey anti-mouse AlexaFluor647 (Molecular Probes #A31571, 1:250) in combination with ActinGreen 488 
ReadyProbes Reagent (Thermo Fisher, #R37110) and NucBlue Fixed Cell ReadyProbes Reagent (Thermo Fisher, 
#R37606) for 1 h at room temperature as explained  previously19. Images were acquired on the InCell 6000 (GE 
Healthcare Life Sciences).
RNA isolation. RNA was isolated from the microfluidic chips using TRI-reagent (Sigma Aldrich). In a nut-
shell, 100 µL of TRI-reagent was added to the top inlet and 25 µL to the top outlet of the OrganoPlate. The plate 
was placed under an angle for 15 min. For standard HIO cultures, HIO were harvested from Matrigel droplets 
using cold PBS (Gibco), pelleted and resuspended in TRI-reagent. The lysed cells were harvested and a phenol/
chloroform extraction was performed according to manufacturer’s instructions. Isolated RNA was quantified on 
the Nanodrop 2000 (Thermo Fisher), was treated with amplification grade DNAse I (Invitrogen) for 15 min at 
room temperature and inactivated with incubation with EDTA.
Reverse transcription and qRT‑PCR. RNA quality control was performed using the 2100 Bioanalyzer 
microfluidic gel electrophoresis system (Agilent). Removal of gDNA contamination was performed using the 
Heat&Run gDNA removal kit (ArticZymes). cDNA synthesis was performed using the iScript Advanced cDNA 
Synthesis Kit (Bio-Rad) with 600 ng of total RNA input. Each qPCR reaction used 5 ng cDNA equivalents of 
RNA as input and a SYBR Green I mastermix (Bio-Rad) in a total volume of 5µL. All qPCR reactions were run 
in duplicate in 384-well plates on a CFX384 instrument (Bio-Rad). All data presented was normalized to house-
keeping genes RPS18, HPRT1, GUSB and YWHAZ (Table 4).
RNA‑sequencing. Library preparations, sequencing reactions were conducted at GENEWIZ, LLC. (South 
Plainfield, NJ, USA) and have been described  before60,61. RNA samples were quantified using Qubit 2.0 Fluo-
rometer (Life Technologies, Carlsbad, CA, USA) and RNA integrity was checked with 4200 TapeStation (Agilent 
Technologies, Palo Alto, CA, USA). Ribosomal RNA depletion was performed using Ribozero rRNA Removal 
Kit (Illumina, San Diego, CA, USA). RNA sequencing library preparation used NEBNext Ultra RNA Library 
Prep Kit for Illumina by following the manufacturer’s recommendations (NEB, Ipswich, MA, USA). Briefly, 
enriched RNAs were fragmented for 15 min at 94 °C. First strand and second strand cDNA were subsequently 
synthesized. cDNA fragments were end repaired and adenylated at 3′ends, and universal adapter was ligated 
to cDNA fragments, followed by index addition and library enrichment with limited cycle PCR. Sequencing 
libraries were validated using the Agilent Tapestation 4200 (Agilent Technologies, Palo Alto, CA, USA), and 
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quantified by using Qubit 2.0 Fluorometer (Invitrogen, Carlsbad, CA) as well as by quantitative PCR (Applied 
Biosystems, Carlsbad, CA, USA). The sequencing libraries were multiplexed and clustered on one lane of a flow-
cell and loaded on the Illumina HiSeq instrument according to manufacturer’s instructions. The samples were 
sequenced using a HiSeq 2 × 150 Paired End configuration. Image analysis and base calling were conducted by 
the HiSeq Control Software. Raw sequence data (.bcl files) generated from Illumina HiSeq was converted into 
fastq files and de-multiplexed using Illumina’s bcl2fastq 2.17 software. One mis-match was allowed for index 
sequence identification.
Gene expression quantification and differential gene expression analysis. Quality reports for 
raw reads were generated using FastQC toolkit, followed by Trimmomatic trimming of raw reads using the 
following parameters (adapters: TruSeq3-PE.fa; sliding window:4; leading quality threshold:3). Obtained reads 
after trimming were checked for quality with FastQC and MultiQC toolkits and were mapped against the human 
genome (GRCh38.98) using STAR 62 and  Kallisto63. Gene counts from each sample were used for subsequent 
analyses; STAR generated counts were investigated using DESeq2  package64 and Kallisto – with Sleuth  package65; 
this strategy was chosen to specifically compare for mapping accuracy and potential batch effects. DESeq2 was 
subsequently used to estimate variance-mean dependence in generated count data, followed by variance stabiliz-
ing transformation to test for differential expression using a model based on the negative binomial distribution. 
Fold changes and adjusted p-values (q-value) for sample comparison were calculated setting at alpha = 0.05 and 
pAdjustMethod = “BH”. Differentially expressed genes (q-value < 0.05) were analysed based on log2fold change 
as well as rlog transformed variability across different conditions. Heatmaps were built selecting distance func-
tion: “euclidean” and hierarchical clustering function: “complete”. Statistical analysis and visualization of func-
tional profiles for genes was performed with Clusterprofile package based on GO and KEGG  datasets66. All 
analyses performed with R for statistical programming (version 3.5.3) on the RStudio IDE (Version 1.2.5019). 
Additional datasets used for comparison:  GSE10947124 (Caco-2 Transwell, Caco-2 gut-on-a-chip, duodenum-
on-a-chip, duodenum organoid samples),  GSE1493830 (human normal duodenum/jejunum/ileum samples), 
 GSE925431 (human normal colon samples). All additional samples were analysed and normalized based on the 
platform used for read generation integrating into existing processing pipeline.
“MetaCore from Clarivate Analytics” was used to parse multiple disease and metabolic pathways against 
the gene set of interest (selecting upregulated genes above the threshold p < 0.05). Pathways were generated 
using the following parameters (network building: direct interactions, species: human, selecting for binding 
and functional interactions).
Investigation of inflammatory cytokine expression in IBD patients. Gene expression across 
patients samples was examined in curated databases using  Genevestigator67. Dataset GSE59071 allowed the 
investigation of gene expression in the colonic mucosa of healthy and IBD  patients38.
Table 4.  Probes used in the study.
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Statistics. Data analysis was performed with GraphPad Prism software version 8 (GraphPad Software, La 
Jolla, CA, USA). All values are expressed as mean ± standard error of the mean (SEM), unless indicated other-
wise. A two-tailed, unpaired Student’s t-test was used to determine the statistical significance when two groups 
of data were analysed. When more than two groups were analyzed, parametrical ANOVA was used. Differences 
with p values ≤ 0.05 were considered significant (ns p > 0.05, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001). 
Results shown are from one representative experiment containing at least three technical replicates. The number 
of technical replicates is presented in the legend of each figure.
Data availability
The datasets generated during and/or analysed during the current study are available in the GEO repository, 
[GSE153191].
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